Elicera Therapeutics has announced that Karin Hoogendoorn has been appointed to the Board.
The company works for an accelerated development of Elicera’s next generation oncolytic virus and CAR T-cell clinical and pre-clinical programs, together with its iTANK platform for optimizing CAR T-cells.
Hoogendoorn has 25 years of experience in the pharmaceutical industry, predominantly in the field of advanced therapy medicinal products (ATMPs), monoclonal antibodies and viral vector based vaccines. She has held various roles of increasing responsibility covering chemical, manufacturing and controls (CMC) and regulatory affairs from pre-clinical to commercial phases for small, medium and large pharmaceutical companies in the Netherlands, Switzerland, Sweden and Japan. Currently, she is a member of the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP).
“I am delighted to join Elicera at this exciting time for both the company as for cell and gene therapy in general,” says Hoogendoorn. “Elicera’s pipeline of oncolytic virus and CAR-T cell drug candidates has the potential to significantly improve the efficacy of combination therapies, while I believe iTANK represents a major breakthrough with its ability to broaden CD8+ T-cell activation.”